Tumorigenic and adhesive properties of heparanase

Seminars in Cancer Biology

Volumn 20, Issue 3, 2010, Pages 153-160

  Levy Adam, Flonia ^a   Ilan, Neta ^a   Vlodavsky, Israel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Akt; Heparanase; Hpa2; MMP; Src

Indexed keywords

GLYCOSIDASE; HEPARANASE; HEPARANASE 2; MATRIX METALLOPROTEINASE; PROTEIN TYROSINE KINASE; RAC PROTEIN; SYNDECAN; UNCLASSIFIED DRUG;

CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; ENZYME ACTIVITY; HUMAN; METASTASIS; PROGNOSIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; CELL ADHESION; DISEASE PROGRESSION; GLUCURONIDASE; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PROTEOME; SIGNAL TRANSDUCTION;

EID: 77956618577     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.06.005     Document Type: Review

References (106)

1. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009, 28:15-33.
2. Pillay V., Dass C.R., Choong P.F. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007, 25:33-39.
3. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006, 6:764-775.
4. Rowe R.G., Weiss S.J. Breaching the basement membrane: who, when and how?. Trends Cell Biol 2008, 18:560-574.
5. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729-777.
6. Kjellen L., Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991, 60:443-475.
7. Fransson L.A., Belting M., Cheng F., Jonsson M., Mani K., Sandgren S. Novel aspects of glypican glycobiology. Cell Mol Life Sci 2004, 61:1016-1024.
8. Cole G.J., Halfter W. Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect Dev Neurobiol 1996, 3:359-371.
9. Iozzo R.V. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998, 67:609-652.
10. Kramer K.L., Yost H.J. Heparan sulfate core proteins in cell-cell signaling. Annu Rev Genet 2003, 37:461-484.
11. Iozzo R.V., San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001, 108:349-355.
12. Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002, 2:521-528.
13. Simons M., Horowitz A. Syndecan-4-mediated signalling. Cell Signal 2001, 13:855-862.
14. Timpl R., Brown J.C. Supramolecular assembly of basement membranes. BioEssays 1996, 18:123-132.
15. Udo Hacker K.Na.N.P. Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 2005, 6:530-541.
16. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci 2003, 28:145-151.
17. Bashkin P., Doctrow S., Klagsbrun M., Svahn C.M., Folkman J., Vlodavsky I. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989, 28:1737-1743.
18. Folkman J., Klagsbrun M., Sasse J., Wadzinski M., Ingber D., Vlodavsky I. A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 1988, 130:393-400.
19. Patel V.N., Knox S.M., Likar K.M., Lathrop C.A., Hossain R., Eftekhari S., et al. Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis. Development 2007, 134:4177-4186.
20. Vlodavsky I., Bar-Shavit R., Ishai-Michaeli R., Bashkin P., Fuks Z. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?. Trends Biochem Sci 1991, 16:268-271.
21. Vlodavsky I., Miao H.Q., Medalion B., Danagher P., Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 1996, 15:177-186.
22. McKenzie E.A. Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 2007, 151:1-14.
23. Bar-Ner M., Kramer M.D., Schirrmacher V., Ishai-Michaeli R., Fuks Z., Vlodavsky I. Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells. Int J Cancer 1985, 35:483-491.
24. Nakajima M., Irimura T., DiFerrante D., DiFerrante N., Nicolson G.L. Heparan sulfate degradation: relation to tumor invasion and metastatic properties of Mouse B 16 Melanoma sublines. Science (Wash DC) 1983, 220:611-613.
25. Vlodavsky I., Fuks Z., Bar-Ner M., Ariav Y., Schirrmacher V. Lymphoma cells mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relation to tumor cell metastasis. Cancer Res 1983, 43:2704-2711.
26. Gilat D., Hershkoviz R., Goldkorn I., Cahalon L., Korner G., Vlodavsky I., et al. Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J Exp Med 1995, 181:1929-1934.
27. Hulett M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J., Parish C.R. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999, 5:803-809.
28. Kussie P.H., Hulmes J.D., Ludwig D.L., Patel S., Navarro E.C., Seddon A.P., et al. Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 1999, 261:183-187.
29. Toyoshima M., Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 1999, 274:24153-24160.
30. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999, 5:793-802.
31. Goldshmidt O., Zcharia E., Cohen M., Aingorn H., Cohen I., Nadav L., et al. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 2003, 17:1015-1025.
32. Levy-Adam F., Feld S., Suss-Toby E., Vlodavsky I., Ilan N. Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS ONE 2008, 3:e2319.
33. Zetser A., Bashenko Y., Miao H.-Q., Vlodavsky I., Ilan N. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 2003, 63:7733-7741.
34. Casu B., Vlodavsky I., Sanderson R.D. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 2008, 36:195-203.
35. Ferro V., Hammond E., Fairweather J.K. The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 2004, 4:693-702.
36. Ilan N., Elkin M., Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006, 38:2018-2039.
37. Vlodavsky I., Ilan N., Naggi A., Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007, 13:2057-2073.
38. Vreys V., David G. Mammalian heparanase: what is the message?. J Cell Mol Med 2007, 11:427-452.
39. Ogren S., Lindahl U. Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J Biol Chem 1975, 250:2690-2697.
40. Thunberg L., Backstrom G., Wasteson A., Robinson H.C., Ogren S., Lindahl U. Enzymatic depolymerization of heparin-related polysaccharides. Substrate specificities of mouse mastocytoma and human platelet endo-beta-d-glucuronidases. J Biol Chem 1982, 257:10278-10282.
41. Miao H.Q., Liu H., Navarro E., Kussie P., Zhu Z. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 2006, 13:2101-2111.
42. Doweck I., Kaplan-Cohen V., Naroditsky I., Sabo E., Ilan N., Vlodavsky I. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 2006, 8:1055-1061.
43. El-Assal O.N., Yamanoi A., Ono T., Kohno H., Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001, 7:1299-1305.
44. Maxhimer J.B., Quiros R.M., Stewart R., Dowlatshahi K., Gattuso P., Fan M., et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 2002, 132:326-333.
45. Nagler R., Ben-Izhak O., Cohen-Kaplan V., Shafat I., Vlodavsky I., Akrish S., et al. Heparanase up-regulation in tongue cancer: tissue and saliva analysis. Cancer 2007, 110:2732-2739.
46. Tang W., Nakamura Y., Tsujimoto M., Sato M., Wang X., Kurozumi K., et al. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 2002, 15:593-598.
47. Barash U., Cohen-Kaplan V., Arvatz G., Gingis-Velitski S., Levy-Adam F., Nativ O., et al. A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J 2010, 24:1239-1248.
48. Cohen I., Pappo O., Elkin M., San T., Bar-Shavit R., Hazan R., et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006, 118:1609-1617.
49. Doviner V., Maly B., Kaplan V., Gingis-Velitski S., Ilan N., Vlodavsky I., et al. Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol 2006, 19:878-888.
50. Yang Y., Macleod V., Bendre M., Huang Y., Theus A.M., Miao H.Q., et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005, 105:1303-1309.
51. Lerner I., Baraz L., Pikarsky E., Meirovitz A., Edovitsky E., Peretz T., et al. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 2008, 14:668-676.
52. Elkin M., Ilan N., Ishai-Michaeli R., Friedmann Y., Papo O., Pecker I., et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001, 15:1661-1663.
53. Gingis-Velitski S., Zetser A., Flugelman M.Y., Vlodavsky I., Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004, 279:23536-23541.
54. Zcharia E., Zilka R., Yaar A., Yacoby-Zeevi O., Zetser A., Metzger S., et al. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005, 19:211-221.
55. Fux L., Ilan N., Sanderson R.D., Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem Sci 2009, 34:511-519.
56. Beauvais D.M., Rapraeger A.C. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2004, 2:3.
57. Couchman J.R. Syndecans: proteoglycan regulators of cell-surface microdomains?. Nat Rev Mol Cell Biol 2003, 4:926-937.
58. Saoncella S., Echtermeyer F., Denhez F., Nowlen J.K., Mosher D.F., Robinson S.D., et al. Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc Natl Acad Sci USA 1999, 96:2805-2810.
59. Bass M.D., Roach K.A., Morgan M.R., Mostafavi-Pour Z., Schoen T., Muramatsu T., et al. Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix. J Cell Biol 2007, 177:527-538.
60. Dovas A., Yoneda A., Couchman J.R. PKCbeta-dependent activation of RhoA by syndecan-4 during focal adhesion formation. J Cell Sci 2006, 119:2837-2846.
61. Tkachenko E., Elfenbein A., Tirziu D., Simons M. Syndecan-4 clustering induces cell migration in a PDZ-dependent manner. Circ Res 2006, 98:1398-1404.
62. Tkachenko E., Rhodes J.M., Simons M. Syndecans: new kids on the signaling block. Circ Res 2005, 96:488-500.
63. Gingis-Velitski S., Zetser A., Kaplan V., Ben-Zaken O., Cohen E., Levy-Adam F., et al. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 2004, 279:44084-44092.
64. Vreys V., Delande N., Zhang Z., Coomans C., Roebroek A., Durr J., et al. Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J Biol Chem 2005, 280:33141-33148.
65. Abboud-Jarrous G., Atzmon R., Peretz T., Palermo C., Gadea B.B., Joyce J.A., et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 2008, 283:18167-18176.
66. Abboud-Jarrous G., Rangini-Guetta Z., Aingorn H., Atzmon R., Elgavish S., Peretz T., et al. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 2005, 280:13568-13575.
67. Goldshmidt O., Nadav L., Aingorn H., Irit C., Feinstein N., Ilan N., et al. Human heparanase is localized within lysosomes in a stable form. Exp Cell Res 2002, 281:50-62.
68. Levy-Adam F., Abboud-Jarrous G., Guerrini M., Beccati D., Vlodavsky I., Ilan N. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 2005, 280:20457-20466.
69. Nadav L., Eldor A., Yacoby-Zeevi O., Zamir E., Pecker I., Ilan N., et al. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci 2002, 115:2179-2187.
70. Zetser A., Levy-Adam F., Kaplan V., Gingis-Velitski S., Bashenko Y., Schubert S., et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004, 117:2249-2258.
71. Hulett M.D., Hornby J.R., Ohms S.J., Zuegg J., Freeman C., Gready J.E., et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000, 39:15659-15667.
72. Woods A., Couchman J.R. Syndecan-4 and focal adhesion function. Curr Opin Cell Biol 2001, 13:578-583.
73. Sotnikov I., Hershkoviz R., Grabovsky V., Ilan N., Cahalon L., Vlodavsky I., et al. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol 2004, 172:5185-5193.
74. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526.
75. Yang Y., MacLeod V., Dai Y., Khotskaya-Sample Y., Shriver Z., Venkataraman G., et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007, 110:2041-2048.
76. McKenzie E., Tyson K., Stamps A., Smith P., Turner P., Barry R., et al. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 2000, 276:1170-1177.
77. Fuki I.V., Kuhn K.M., Lomazov I.R., Rothman V.L., Tuszynski G.P., Iozzo R.V., et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 1997, 100:1611-1622.
78. Stanford K.I., Bishop J.R., Foley E.M., Gonzales J.C., Niesman I.R., Witztum J.L., et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest 2009, 119:3236-3245.
79. Fears C.Y., Woods A. The role of syndecans in disease and wound healing. Matrix Biol 2006, 25:443-456.
80. Ben-Zaken O., Gingis-Velitski S., Vlodavsky I., Ilan N. Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 2007, 361:829-834.
81. Nadir Y., Brenner B., Zetser A., Ilan N., Shafat I., Zcharia E., et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006, 4:2443-2451.
82. Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I., Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006, 66:1455-1463.
83. Cohen-Kaplan V., Doweck I., Naroditsky I., Vlodavsky I., Ilan N. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 2008, 68:10077-10085.
84. Haskell M.D., Slack J.K., Parsons J.T., Parsons S.J. c-Src tyrosine phosphorylation of epidermal growth factor receptor, P190 RhoGAP, and focal adhesion kinase regulates diverse cellular processes. Chem Rev 2001, 101:2425-2440.
85. Barbero S., Mielgo A., Torres V., Teitz T., Shields D.J., Mikolon D., et al. Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res 2009, 69:3755-3763.
86. Finlay D., Howes A., Vuori K. Critical role for caspase-8 in epidermal growth factor signaling. Cancer Res 2009, 69:5023-5029.
87. Benes P., Vetvicka V., Fusek M. Cathepsin D - many functions of one aspartic protease. Crit Rev Oncol Hematol 2008, 68:12-28.
88. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010, 11:23-36.
89. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
90. Cao Y., Li H., Deb S., Liu J.P. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002, 21:3130-3138.
91. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
92. Dufour A., Sampson N.S., Zucker S., Cao J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol 2008, 217:643-651.
93. Redondo-Munoz J., Ugarte-Berzal E., Terol M.J., Van den Steen P.E., Hernandez del Cerro M., Roderfeld M., et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell. 2010, 17:160-172.
94. Purushothaman A., Chen L., Yang Y., Sanderson RD Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008, 283:32628-32636.
95. Sanderson R.D., Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 2008, 25:149-159.
96. Zcharia E., Jia J., Zhang X., Baraz L., Lindahl U., Peretz T., et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE 2009, 4:e5181.
97. Zcharia E., Metzger S., Chajek-ShaulL T., Aingorn H., Elikn M., Friedmann Y., et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004, 18:252-263.
98. Szymczak M., Kuzniar J., Klinger M. The role of heparanase in diseases of the glomeruli. Arch Immunol Ther Exp (Warsz) 2010, 58:45-56.
99. van den Hoven M.J., Rops A.L., Vlodavsky I., Levidiotis V., Berden J.H., van der Vlag J. Heparanase in glomerular diseases. Kidney Int 2007, 72:543-548.
100. Levidiotis V., Freeman C., Tikellis C., Cooper M.E., Power D.A. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 2004, 15:68-78.
101. Levidiotis V., Kanellis J., Ierino F.L., Power D.A. Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int 2001, 60:1287-1296.
102. Levidiotis V., Freeman C., Tikellis C., Cooper M.E., Power D.A. Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology 2005, 10:167-173.
103. Waterman M., Ben-Izhak O., Eliakim R., Groisman G., Vlodavsky I., Ilan N. Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 2007, 20:8-14.
104. Li R.W., Freeman C., Yu D., Hindmarsh E.J., Tymms K.E., Parish C.R., et al. Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 2008, 58:1590-1600.
105. Cohen-Kaplan V., Naroditsky I., Zetser A., Ilan N., Vlodavsky I., Doweck I. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 2008, 123:2566-2573.
106. Okawa T., Naomoto Y., Nobuhisa T., Takaoka M., Motoki T., Shirakawa Y., et al. Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2. Clin Cancer Res 2005, 11:7995-8005.